|
Date
|
Title
|
Download
|
|---|---|---|
|
12.10.07
|
Vion Presents Preliminary Data from its Pivotal Phase II Trial of Cloretazine® (VNP40101M) in Acute Myelogenous Leukemia at ASH Annual Meeting |
 |
|
12.6.07
|
Vion To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine® (VNP40101M) at the American Society of Hematology Meeting. Company to Hold Conference Call on Monday, December 10, 2007 |
|
|
12.4.07
|
Vion Announces Initiation of Clinical Trial of Cloretazine® (VNP40101M) in Combination with Stem Cell Transplantation |
|
|
11.7.07
|
Vion Reports 2007 Third Quarter and Nine-Month Results |
|
|
11.6.07
|
Vion to Host Conference Call To Discuss 2007 Third Quarter and Nine-Month Financial Results |
|
|
9.18.07
|
Vion Receives Notice from Nasdaq |
|
|
9.17.07
|
Vion Announces Initiation of a Phase I/II Trial of Cloretazine® (VNP40101M) in Combination with Temodar® in Adult Brain Tumors |
|
|
9.10.07
|
Vion To Present at 20th Annual Bear Stearns Healthcare Conference |
|
|
8.15.07
|
Vion Pays Interest on 7.75% Convertible Senior Notes |
|
|
8.15.07
|
Vion Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine® (VNP40101M) in Elderly AML |
|
|
8.08.07
|
Vion Reports 2007 Second Quarter and Six-Month Results |
|
|
8.07.07
|
Vion to Host Conference Call To Discuss 2007 Second Quarter and Six-Month Financial Results |
|
|
6.25.07
|
Vion to Hold Annual Meeting of Stockholders |
|
|
6.11.07
|
Vion Presents Clinical Data from a Phase II Trial of Cloretazine® (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting |
|
|
5.23.07
|
Vion Announces Suspension of Phase III Trial in Relapsed AML |
|
|
5.8.07
|
Vion Reports 2007 First Quarter Financial Results |
|
|
5.4.07
|
Vion to Host Conference Call To Discuss 2007 First Quarter Financial Results |
|
|
4.23.07
|
Vion to Present at Fortis Bank Biotechnology Conference |
|
|
4.13.07
|
Vion Presents Data on Cloretazine® (VNP40101M) at the 100th Annual Meeting of the American Association of Cancer Research (AACR) |
|
|
4.11.07
|
Dr. James Tanguay Joins Vion Pharmaceuticals’ Senior Management Team |
|
|
3.22.07
|
Vion Extends Manufacturing Agreement with SAFC for Cloretazine® (VNP40101M) |
|
|
3.2.07
|
Vion Reports 2006 Fourth Quarter and Year-End Financial Results |
|
|
3.1.07
|
Vion to Host Conference Call To Discuss Fourth Quarter and Year-End Financial Results |
|
|
2.20.07
|
Vion Completes Private Placement of Convertible Notes and Warrants |
|
|
2.14.07
|
Vion Enters into an Agreement to Sell Convertible Senior Notes and Warrants |
|
|
1.25.07
|
Vion Proceeding to Second Stage of Pivotal Phase II Trial of Cloretazine® (VNP40101M) in Elderly AML |
|
| 2006 | ||
|
12.13.06
|
Vion Enters into Manufacturing Agreement for Cloretazine® (VNP40101M) with Ben Venue Laboratories |
|
|
12.11.06
|
Vion Presents Data on Cloretazine (VNP40101M) at the 48th Annual American Society of Hematology (ASH) Meeting |
|
|
11.13.06
|
Vion Reaches Midpoint of Patient Accrual to Cloretazine® (VNP40101M) Phase III Trial |
|
|
11.9.06
|
Vion to Host Conference Call To Discuss Third Quarter and Nine Month Financial Results |
|
|
11.9.06
|
Vion Reports 2006 Third Quarter and Nine-Month Financial Results |
|
|
11.6.06
|
Vion to Present at Rodman & Renshaw and CIBC World Markets Conferences |
|
|
10.30.06
|
Vion to Present at C.E. Unterberg, Towbin Life Sciences Conference |
|
|
10.26.06
|
Vion Presents Initial Data from a Phase II trial of Cloretazine® (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer |
|
|
9.21.06
|
Vion to Present at UBS Global Life Sciences Conference |
|
|
9.11.06
|
Vion to Present at Bear Stearns and Think Equity Conferences |
|
|
8.8.06
|
Vion Reports 2006 Second Quarter Financial Results |
|
|
8.8.06
|
Vion to Host Conference Call to Discuss Second Quarter Financial Results |
|
|
6.17.06
|
Aileen Ryan Joins Vion’s Senior Management Team |
|
|
6.28.06
|
Ian Williams Elected to Vion Board of Directors |
|
|
6.26.06
|
Vion to Hold Annual Meeting of Stockholders |
|
|
6.5.06
|
Vion Presents Data on Cloretazine® In Elderly De Novo Acute Myelogenous Leukemia at ASCO Meeting |
|
|
5.31.06
|
Vion Provides Update for Clinical and Preclinical Programs |
|
|
5.30.06
|
Vion to Hold Conference Call |
|
|
5.24.06
|
Vion Initiates Pivotal Phase 2 Trial of Single Agent Cloretazine® in Elderly Patients with De Novo Poor-Risk Acute Myelogenous Leukemia |
|
|
5.8.06
|
Vion Reports 2006 First Quarter Financial Results |
|
|
4.4.06
|
Vion Presents Preclinical Data on Cloretazine® (VNP40101M), a Hypoxia-Selective Compound (VNP40541) and Hydrazones at AACR Meeting |
|
|
2.28.06
|
Vion Reports 2005 Year-End and Fourth Quarter Financial Results |
|
|
1.31.06
|
Vion Announces Plans to Conduct a Pivotal Phase 2 Trial of Cloretazine® in Elderly Poor-Risk Acute Myelogenous Leukemia |
|
|
1.30.06
|
Vion to Host Conference Call |
|
|
1.23.06
|
Vion Receives Orphan Drug Designation for Cloretazine® in Europe for Treatment of Acute Myeloid Leukemia |
|
|
1.10.06
|
Meghan Fitzgerald Joins Vion’s Senior Management Team |
|
